NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

GlucoTrack, Inc. (GCTK) Stock Analysis

GlucoTrack, Inc. (GCTK) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GCTK

$0.64

−$0.01 (−1.86%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GCTK with… →

GCTK Key Statistics

As of Oct 21, 2026
Trading
Open
$0.65
Previous Close
$0.65
Day's Range
0.63–0.67
52-Week Range
0.59–112.50
Volume
73.91K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.73
Valuation
Market Cap
$650.51K
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−123.15
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$19.39M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.02M
1-Year Return
−99.36%
Dividend and dates
Avg Volume
1.92M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GCTK closed at $0.64, −99.36% over 1 year.

GlucoTrack, Inc. (GCTK) has a market capitalization of $650.51K.

In fiscal 2025, GCTK reported revenue of $0.00.

GCTK Stock Return by Calendar Year

GlucoTrack, Inc. (GCTK) 10-year return: what $10,000 became

1 year
$10,000 $64
−99.36%
5 years
$10,000 $0.01
−99.9999%
10 years
$10,000 $0.002
−99.99998%

If you had invested $10,000 in GlucoTrack, Inc. (GCTK) 10 years ago, at the close on October 21, 2016, it would have been worth $0.002 at the close on October 21, 2026: −99.99998% in total, −78.44% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−98.90%
2025−99.14%
2024−71.53%
2023−81.42%
2022−66.19%
2021−9.64%
2020−40.83%
2019+20.00%
2018−75.00%
2017−20.00%
2016 (partial year)−12.89%

As of October 21, 2026.

GCTK Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$19.39M—
2024$0.00−$22.60M—
2023$0.00−$7.10M—
2022$0.00−$4.44M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$16.09M−$19.39M—
2024$0.00—−$14.55M−$22.60M—
2023$0.00—−$7.10M−$7.10M—
2022$0.00—−$4.43M−$4.44M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values GlucoTrack, Inc. (GCTK) at $650.51K. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 15 employees.

The most recent close on file for GCTK is $0.64, dated October 21, 2026. That is −$0.01 (−1.86%) against the previous close. The 52-week range on file runs from $0.59 to $112.50. The latest close sits 8.31% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $19.39M. Earnings per share on a trailing basis come to −123.15.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is −99.36%. Measured over 10 years, that is −78.44% a year compounded. Beta against the wider market is reported at 0.73. Daily returns over the trailing 10 years annualize to a volatility of 240.32%.

Growth & Income

No dividend is on file for GCTK.

2026 is still running; the total return is −98.90% year to date. The strongest complete calendar year on file is 2019 at +20.00%; the weakest is 2025 at −99.14%. Of the 9 complete calendar years on file, 1 finished higher.

Peer Comparison

GlucoTrack, Inc. (GCTK) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GlucoTrack, Inc. GCTK $650.51K —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. GlucoTrack, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About GlucoTrack, Inc.

GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

Visit website →